A web‐based registry of inherited bleeding disorders in the region of Emilia‐Romagna: results at three and a half years
暂无分享,去创建一个
M. Marietta | A. Tagliaferri | G. Rivolta | C. Pattacini | A. TAGLIAFERRI | G. F. RIVOLTA | C. BIASOLI | L. VALDRÉ | G. RODORIGO | M. D’INCÁ | S. MORATELLI | P. ALBERTINI | D. VINCENZI | M. C. ARBASI | M. MARIETTA | C. PATTACINI | P. Albertini | L. Valdrè | G. Rodorigo | M. D'Incà | C. Biasoli | S. Moratelli | M. Arbasi | D. Vincenzi | M. D'inca | M. C. Arbasi
[1] H. Lenk. The German Registry of immune tolerance treatment in hemophilia--1999 update. , 2000, Haematologica.
[2] Massimo Pandolfo,et al. Molecular Basis , 2022 .
[3] G. Mariani,et al. International Immune Tolerance Registry, 1997 Update , 1999, Vox Sanguinis.
[4] C. Kessler,et al. The molecular basis of haemophilia B , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] J. Oldenburg,et al. Haemophilia A: from mutation analysis to new therapies , 2005, Nature Reviews Genetics.
[6] C. F. Bryan,et al. Annual Report 2006 , 2007 .
[7] J. Batlle,et al. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[8] Mannucci,et al. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] J. Katz,et al. The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors , 2002, Thrombosis and Haemostasis.
[10] A. Gogh. The impact of information technology. , 1997, Caring : National Association for Home Care magazine.
[11] D. Green. The management of acquired haemophilia , 2006 .
[12] R. I. Baker,et al. The impact of information technology on haemophilia care , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[13] D. Dimichele,et al. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias , 2004, Journal of Thrombosis and Haemostasis.
[14] C. Müller,et al. Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data , 2001, British journal of haematology.
[15] P. Giangrande,et al. Treatment of haemophilia in the United Kingdom 1981-1996. , 2001 .
[16] S. Darby,et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99 , 2004, Journal of thrombosis and haemostasis : JTH.
[17] M. Poon. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[18] G. Lippi,et al. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. , 2001, Blood.
[19] S. Schulman. Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness , 2000, Seminars in thrombosis and hemostasis.
[20] Sumon YusufPhotoshare. Care , 1890, The Hospital.